Head Genetics Division, Department of Pediatrics , Associate Professor, King Saud bin Abdulaziz University for Health Sciences , MNG-HA
Dr. Majid Alfadhel is a Genetic and Pediatric Consultant at National Guard Health Affairs. Additionally, Dr. Alfadhel has been an associate professor at King Saud bin Abdulaziz University for the past five years. Alfadhel’s impressive educational background includes a Master’s degree in Epidemiology from the University of British Columbia, as well as fellowships in Neurometabolics and Biochemical Genetics.
Eng. Nizar Al-Hariri comes with over 23 years’ of successful track record of business development in both government and private sectors. Experienced across all aspects of business developments from concept to JV set-ups, contractual negotiations and funding arrangements to major project management, strategic planning and organization structuring. He has proven ability in developing business strategies and plans based on exceptional analytical skills, achieving business goals and taking full P&L responsibility. Having worked in SIDF for ten years and managed Capital Advisory Group for five, he has a recognized management and consultancy records appointed him to manage the advisory services for the Economic Offset Program, EOP and Public Investment Fund, PIF between 2003 and 2006. Later, Eng. Al-Hariri was assigned as CEO for CAD Middle East for Pharmaceutical Industries. He was responsible for introducing a ground breaking concept of building the first GMP state-of-the-art Active Pharmaceutical Ingredients (API) facility in Saudi Arabia and the MENA region.
Eng. Nizar Al-Hariri has a BSc in Chemical Engineering from King Saud University, and post graduate from the University of Cambridge, Engineering Dept. in Design, Manufacture & Management – ACDMM
Abdulmohsen Almajnouni is currently the Chief Executive Officer (CEO) of Research Products Development Company (RPDC). Prior to that, he was the Executive Director of the Strategic Initiatives and as well the Managing Director of Energy and downstream chemicals industry, Saudi Arabia General Investment Authority (SAGIA).
He has more than 24 years of experience in gas processing and treating, refining and petrochemicals, utilities, and exploration and production. Abdulmohsen was previously the Refining and Petrochemical Leader for General Electric in Saudi Arabia, promoting GE’s products and services in the region. He had prior experience as the Global Process Domain Director at SABIC’s Manufacturing Center of Excellence, and consulted on process engineering for SABIC’s sites. He began his career at Saudi Aramco in 1988, before moving to other industrial experiences.
Abdulmohsen earned a BS from King Fahd University of Petroleum and Minerals, and a Master of Engineering from Cornell Univers
ity, Ithaca, NY, USA, both in chemical engineering. He is the chair of American Institute of Chemical Engineers (AIChE) Saudi Arabia Section (SAS-AIChE) and a member of AIChE’s International Committee.
Acting Vice President for the Pharmaceuticals and Biotechnology Cluster, Industrial Clusters.
Eng. Abdullah Al-Mintashry has a Bachelor Degree in Chemical Engineering from King Fahd University of Petroleum and Minerals (KFUPM) , Dhahran , Saudi Arabia and a Master Degree in Engineering Management from the University of Tennessee , United States. He has more than 17 years of accumulated experience assuming various roles at SABIC and National Industrial Cluster Development Program (NICDP).
Currently, he is working in NICDP as an Acting Vice President for the Pharmaceuticals and Bio-Technology Cluster ,. NICDP is a government organization, part of the Saudi Ministry of Energy, Industry and Mineral Resources. NICDP role is to provide support in identification and provocation of key industrial enablers from different perspectives in alignment with other government agencies to support the industrial and manufacturing sectors in the kingdom.
The Pharma & Biotech sector has been identified under vision 2030 as strategic and national security segment in the National Transformation Program (NTP 1.0) as well as the recently established National Industrial Development and Logistics Program (NIDLP)
Chairman, Intensive Care Department, King Abdulaziz Medical City Riyadh
Chairman, Intensive Care Department, Medical Director, Respiratory Services, Professor, College
of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City
Riyadh, Kingdom of Saudi Arabia.
Dr. Arabi obtained his Internal Medicine Training at Wayne State University, Detroit, MI, USA (1992-1994), then he was the Chief Medical Resident at the same institution (1994-1995). He obtained pulmonary and critical care training at the University of Wisconsin, Madison, WI, USA (1995-1998). In 1998, he joined King Abdulaziz Medical City, Riyadh, Saudi Arabia. He is currently the Chairman of the Intensive Care Department and the Medical Director, Respiratory Services. He served as a member of several institutional committees including being the member of several international committees for the Society of Critical Care Medicine (SCCM), American College of Chest Physician (ACCP), and a member of the administrative board of the Saudi Society of Critical Care.
He received multiple grants and awards and has been an investigator on several multicenter international trials including the ADjunctive coRticosteriod trEatment iN criticAlly ilL patients with septic shock / RC12.059 (ADRENAL); Erythropoietin in Traumatic Brain Injury Study / RC10.063 (EPO-TBI); A Prospective Multicentre Randomized Controlled Trial of Early Goal Directed Sedation Compared with Standard Care in Mechanically Ventilated Patients in Intensive Care / RC-12-079 (SPICE III); Severe Acute Respiratory Infection Biological Sampling Study / RC13- 205-R (SARI); OSCILLATE Knowledge Translation – An Audit of ARDS Management / RC14/010 / MCT-04829; A multi-centre randomized controlled trial of an Open Lung Strategy Including Permissive Hypercapnia, Alveolar Recruitment and Low Airway Pressure in patients with acute respiratory distress syndrome (PHARLAP study) / CT13-005R; Prophylaxis of Thromboembolism in Critically ill Patients Using Combined Intermittent Pneumatic Compression and Pharmacologic Prophylaxis Alone: A Multicenter Randomized Controlled Trial (PTCP using CIPC & PPVPPA) / RC12/045/R (PREVENT); Middle East Respiratory Syndrome Corona Virus (MERS-CoV) RC13/244; MERS-CoV Infection Treated with a Combination of Lopinavir / Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-Blind Randomized Trial (MIRACLE Trial) RC15-142-R among the several others.
He has more than 250 publications including articles in the New England Journal of Medicine (NEJM), JAMA, Lancet, and Critical Care Medicine. He has been a reviewer for more than 40 international journals as well as granting agencies.
He led the process of establishing the pharmaceutical products evaluation directorate at SFDA, which is the scientific backbone of the drug sector since 2009. Dr. Almazroo was the first director appointed for pharmaceutical products evaluation. With his colleagues, he developed many of the current scientific practices in the directorate. He also initiated, coordinated and conducted two clinical studies at the University of Pittsburgh Medical Center (UPMC), one of which was Phase I/II – Investigational New Drug (IND) clinical study.
Dr. Almazroo graduated from School of Pharmacy, King Saud University with a Bachelor degree in Pharmaceutical Sciences. In 2009, he was among the top 10% of all graduates in the Master of Sciences in biopharmaceuticals from School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia. On 27 April 2013, he was one of the first Saudi pharmacists to complete the Certificate in Clinical and Translational Sciences (master degree level) from the School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. In 2017, he received his PhD in Pharmaceutical Sciences from University of Pittsburgh. The PhD research was focused on hepatic ischemia and reperfusion injury in liver transplantation. He conducted preclinical and clinical studies, while his research involved in using ex-vivo, in-vivo and simulation models for pharmacokinetics, developed several mass spectrometry assays and utilized PCR techniques for gene characterization.
Advisor to the Minister for Pharmaceutical Sector Development
Advisor to the Minister for Pharmaceutical Sector Development
Ibrahim Aljuffali is the Executive Vice President for Drug Sector at Saudi FDA. Dr. Aljuffali earned his PhD degree in Pharmaceutical sciences from the University of Georgia (UGA) with research emphasis in Nontechnology and Pharmacokinetics/Pharmacodynamics. Dr. Aljuffali also earned a Master of Science Degree in Pharmacy with an emphasis in Regulatory Affairs and graduate diploma in Clinical Trials Design & Management from University of Georgia.
Dr. Aljuffali Also serve as an Associate Professor at King Saud University. He chairs and patriate in different local and national committee related to health and drug regulation.
Director , Medical Biotechnology Park Head, Strategy and Business Development, KAIMRC. MNG-HA
Director , Medical Biotechnology Park
Head, Strategy and Business Development, KAIMRC. MNG-HA
Dr. Haoudi is currently leading the R&D Strategy and Business Development at King Abdullah International Medical Research Center at the Ministry of National Guard Health Affairs and is also Visiting Scientist at Boston Children’s Hospital-Harvard Medical School.
Dr. Haoudi held several senior R&D positions in the academia, government and private sectors including Executive Director for R&D, Founding Vice President for Research at Qatar Foundation and Chairman of Exceptional National Priorities Grants Programs. Dr. Haoudi was also Research Professor of cancer and infectious diseases and a fellow of the US National Institutes of Health. He has also held several other positions in elite research and education institutions including Visiting Professor at Harvard Medical School (USA) and a fellow at Institut Pasteur (France) and had served as consultant and advisor to several biotechnology and pharmaceutical companies.
Dr. Haoudi was elected as a member of the Royal Academy for Science and Technology since 2006 and graduated from University Paris XI, France in 1996 with a doctoral degree in cellular and molecular genetics and received executive education from Harvard Business School in Corporate management and strategy. Dr. Haoudi has also founded and served as the Editor-in-Chief for the Journal of Biomedicine and Biotechnology over 8 years.
Head of King Abdullah International Medical Research Center Jeddah (KAIMRC-J)
Consultant Radiation Oncologist
Head of Radiation Oncology, Princess Norah Oncology Center
Head of King Abdullah International Medical Research Center Jeddah (KAIMRC-J)
Deputy Chairman of Princess Norah Oncology Center, KAMC-WR, NGHA
Dr. Suliman Al Ghamdi joined King Abdulaziz Medical City, Western Region in August 2005 as Associate Consultant, Department of Oncology, and promoted to Consultant position in 2007 and was appointed as Section Head, Radiation Oncology in August 2007. In August 2010, he was appointed as Deputy Chairman, Princess Nourah Oncology Center, King Abdulaziz Medical City, Western Region. In August 2011, he was appointed as Deputy Head, King Abdullah International Medical Research Center, Western Region. In August 13, 2013, Dr. Ghamdi was appointed as the Head of King Abdullah International Medical Research Center – Western Region and up to now is still the head of the Research Center in Jeddah.
Dr. Suliman Al Ghamdi graduated from King Abdulaziz University, Faculty of Medicine, Jeddah, Saudi Arabia in 1997, and completed his internship in the same institution in 1998. He completed his Residency Training Program in Radiation Oncology from January 2000 till December 2004 at Ottawa Regional Cancer Centre, University of Ottawa, Ontario, Canada, followed by fellowship training in Radiation Oncology with sub – specialization in Stereotactic Radiosurgery of Head and Neck, CNS Malignancies and Brachytherapy in 2005. He also obtained FRCPC certificate on May 28, 2004.
Head, Developmental Medicine Department (DMD), KAIMRC
During Dr. Manal Alaamery’s work and career, she established herself as a research leader, received numerous awards, and published in prestigious peer-reviewed scientific journals. Dr. Alaamery also taught several courses, led many initiatives and held several committee positions. Her long-term goal as a scientist is to use her background and expertise in science to contribute to the medical field and develop programs and strategies that could improve research and medicine in the Kingdom of Saudi Arabia. She hope through her work to bridge the gap between research and clinical medicine, translating novel discoveries into clinical tests by using cutting-edge tests. She is currently the Head of Developmental Medicine Department (DMD) at King Abdullah International Medical Research Center (KAIMRC).
In addition, an active research scientist at KAIMRC. Formerly, Dr. Alaamery was an instructor at the Harvard Medical School/ Children’s Hospital Boston. She received her clinical and postgraduate training at Harvard Medical School Genetics Program. Her clinical training at the Laboratory of Molecular Medicine (LMM) at Harvard focused on the areas of Hypertrophic and Dilated Cardiomyopathies, Neurological disorders, Muscular disorders, Hearing loss, Noonan spectrum, Connective tissue disorders, Pharmacogenetics and Cancer genetics. Dr. Alaamery also hold a Doctoral (Ph.D.) degree in Molecular Genetics/Biology from Boston College and a Master of Science degree in Clinical Microbiology from Thomas Jefferson University. In addition, Dr. Alaamery is the Chairman of the Saudi Genome Project satellite KACST-NGHA lab, the principal investigator of the KAIMRC-KACST therapy development joint program, and the co-principal investigator of the genetic track of the Biomedicine Center of Excellence BWH-Harvard affiliated hospital-KACST.
Head of Biotechnology, Badir Program for Technology Incubators Experienced Commercialization Manager with a demonstrated history of working in the research industry
Skilled in Innovation Management, Analytical Skills, Medical Devices, Biomechanics, and Emergency Management. Strong product management professional with a Master of Technology and Innovations Management focused in Biotechnology from The University of Queensland.
Development Medicine Department KAIMRC , Saudi Arabia
Dr.Salam Massadeh has a PhD degree in the field of Nanotechnology in bio-imaging; from the University of East Anglia, United Kingdom. And a Master’s degree, in the field of Drug Delivery Systems, college of pharmacy, University of Reims Champagne Ardennes, France. In addition, she has a Bachelor’s degree in Pharmacy from Jordan University of Science and Technology. Dr.Massadeh is Member of the Royal Pharmacists Society (RPS), United kingdom. And a member of the International Federation of Pharmacists(FIP), and several other bodies.
Dr.Massadeh is experienced in therapy development, drug delivery systems, bio-nanotechnology, and the use of nanotechnology for gene therapy.
In her current position, Dr.Massadeh is leading the therapy development lab under the Developmental Medicine Department (DMD) at KAIMRC. Besides, she is the principle investigator of major research projects, and a co-Investigator of many other research projects related to therapy development, gene therapy, gene discovery and pharmacogenetics. In her current position, she has initiated collaborations with international research groups in her field; she is also keen to work with colleagues from different research areas. Dr.Massadeh has published her research outcomes in international peer reviewed journals. Dr.Massadeh is also a member of editorial boards of scientific journals and scientific books.
Based in Riyadh, Saudi Arabia, Dr. Alya Redhwan is Assistant Professor of Microbiology at Princess Nourah University (PNU) where she also serves as the Coordinator of the Microbiology & Immunology Research Center of its Health Sciences Research Center. In 2018, she became the first ambassador of the UK-based Society of General Microbiology (SGM) in Saudi Arabia. Having undertaken all of her graduate education in England, Dr. Alya Redhwan’s research interests revolve around bacterial virulence mechanisms. Her passion for research extends to the development and empowerment of scientific research in the region and her community where she is now serving as a Vice Dean of Scientific Research for Publishing Affair at PNU